Drug Trial News

RSS

$New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod$

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.

2 Aug 2017

Type 1 diabetes clinical trial reaches halfway point for enrollment and treatment

The Sanford Project: T-Rex Study, a Phase 2 clinical trial conducted collaboratively by Sanford Health and Caladrius Biosciences, Inc., has reached the halfway point for enrollment and treatment.

28 Jul 2017

New trial shows ketamine's effectiveness to treat geriatric depression

Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.

24 Jul 2017

FDA panel recommends new breakthrough gene therapy for B-cell acute lymphoblastic leukemia (ALL)

A Food and Drug Administration (FDA) panel created history by recommending a gene therapy for patients with cancer. In this therapy the patient’s own genes would be modified to fight the cancer cells. The patient’s cells which are thus altered to treat the cancer would thus be termed as “living drugs” as they act as soldiers to treat the cancer. These cells boost up the immune system and help the body fight the cancer.

14 Jul 2017

Erectile dysfunction drug may be used to coat stents in future heart surgeries

Coating stents with an erectile dysfunction drug may be the way forwards in treating stent patients, say researchers.

12 Jul 2017

Novel therapy decreases incidence of bleeding by 87% in hemophilia A patients with inhibitors

An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding episodes by 87%.

10 Jul 2017

Clinical trial shows anti-inflammatory benefits from taking high doses of vitamin D after sunburn

High doses of vitamin D taken one hour after sunburn significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.

6 Jul 2017

Study: Personalized neoantigen vaccine stimulates strong anti-tumor response in melanoma patients

A personal cancer treatment vaccine that targets distinctive "neoantigens" on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

5 Jul 2017

Clinical trial of immunotherapy shows promising results for patients with melanoma brain tumors

Two years ago, when Kathy Roberts was 54, she started having pain in her ankle. She ignored it. Then it became swollen, and she had more and more trouble walking. So she went to a series of doctors trying to figure out the problem.

27 Jun 2017

Experimental drug benefits some patients with advanced kidney cancer

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.

24 Jun 2017

Defining patient centricity

"Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.”

20 Jun 2017

First-ever clinical study for effective treatment of mycetoma begins in Sudan

The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre in Khartoum, Sudan.

19 Jun 2017

Pfizer initiates Phase 1 trial of investigational GBS vaccine

Pfizer Inc. today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection.

19 Jun 2017

New chemoprevention trial hopes to stop dangerous lesions from progressing to cancer

New treatments have extended the lives of many lung cancer patients. However, even better than treating lung cancer would be preventing it from developing in the first place.

15 Jun 2017

UNC researchers evaluate investigational medication for treatment of postpartum depression

Researchers at the University of North Carolina School of Medicine announced the publication of results from a multi-site phase 2 clinical trial with brexanolone, an investigational medication, in the treatment of severe postpartum depression.

13 Jun 2017

Clinical study shows new mechanism that BCG vaccine uses to reverse advanced type 1 diabetes

Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes are being presented at the 75th Scientific Sessions of the American Diabetes Association.

12 Jun 2017

Combination treatment found to effective in patients with tophaceous gout

The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout.

9 Jun 2017

Adding a second HER2-targeted treatment may improve outcomes for some women with breast cancer

A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.

6 Jun 2017

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC).

5 Jun 2017

New targeted oral therapy results in durable responses across many kinds of cancer

Scientists may have developed the first targeted, oral, tumor-type agnostic therapy - a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment resulted in responses in 76% of patients.